(Q34382847)

1 August 2017

1 reference

title

Comparative safety of the different macrolides (English)

1 reference

1 August 2017

Rubinstein E

1

1 reference

1 August 2017

publication date

1 January 2001

1 reference

International Journal of Antimicrobial Agents

1 August 2017

published in

1 reference

1 August 2017

volume

18 Suppl 1

1 reference

1 August 2017

page(s)

S71-6

1 reference

Evaluation of the safety of macrolides

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900397-1

7 January 2021

Erythromycin, clarithromycin, and azithromycin: are the differences real?

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900397-1

7 January 2021

The safety of azithromycin in the treatment of adults with community-acquired respiratory tract infections

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900397-1

7 January 2021

Overview of the tolerability profile of clarithromycin in preclinical and clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900397-1

7 January 2021

An evaluation of tolerance of roxithromycin in adults

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900397-1

7 January 2021

Once weekly azithromycin therapy for prevention of Mycobacterium avium complex infection in patients with AIDS: a randomized, double-blind, placebo-controlled multicenter trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900397-1

7 January 2021

A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900397-1

7 January 2021

Azithromycin in the management of Chlamydia trachomatis infections

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900397-1

7 January 2021

Azithromycin as the first-line treatment of non-gonococcal urethritis (NGU): a study of follow-up rates, contact attendance and patients' treatment preference

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900397-1

7 January 2021

Drug intolerance to high-dose clarithromycin among elderly patients

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900397-1

7 January 2021

A clarithromycin-induced myasthenic syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900397-1

7 January 2021

Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900397-1

7 January 2021

Toxicity of quinolones

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900397-1

7 January 2021

Azithromycin and terfenadine: lack of drug interaction.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900397-1

7 January 2021

QT prolongation and Torsades de Pointes associated with clarithromycin

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900397-1

7 January 2021

Torsades de pointes in two chronic renal failure patients treated with cisapride and clarithromycin

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900397-1

7 January 2021

Torsade de pointes induced by cisapride/clarithromycin interaction

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900397-1

7 January 2021

Torsades de pointes ventricular tachycardia induced by clarithromycin and disopyramide in the presence of hypokalemia

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900397-1

7 January 2021

Symptomatic syndrome of inappropriate antidiuretic hormone secretion associated with azithromycin

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900397-1

7 January 2021

Azithromycin-induced acute interstitial nephritis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900397-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900397-1

7 January 2021

Anaphylaxis to erythromycin

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900397-1

7 January 2021

Theophylline metabolism by human, rabbit and rat liver microsomes and by purified forms of cytochrome P450

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900397-1

7 January 2021

The role of cytochromes P-450 in cyclosporine metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900397-1

7 January 2021

Microsomal enzyme induction, lipoproteins and atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900397-1

7 January 2021

Clinical pharmacokinetics of clarithromycin

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900397-1

7 January 2021

Carbamazepine toxicity induced by clarithromycin coadministration in psychiatric patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900397-1

7 January 2021

Oral cimetidine prolongs clarithromycin absorption

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900397-1

7 January 2021

Torsades de pointes associated with astemizole (Hismanal) therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900397-1

7 January 2021

Concurrent clarithromycin and cyclosporin A treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900397-1

7 January 2021

Pharmacokinetic interactions with digoxin

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900397-1

7 January 2021

Erythromycin-induced digoxin toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900397-1

7 January 2021

Digoxin toxicity due to interaction of digoxin with erythromycin

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900397-1

7 January 2021

Influence of erythromycin pre- and co-treatment on single-dose pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900397-1

7 January 2021

HMG-CoA reductase inhibitors and myotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900397-1

7 January 2021

Clarithromycin lowers plasma zidovudine levels in persons with human immunodeficiency virus infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900397-1

7 January 2021

The effect of azithromycin on the pharmacokinetics of indinavir.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900397-1

7 January 2021

Effect of clarithromycin on the pharmacokinetics of 2',3'-dideoxyinosine in patients who are seropositive for human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900397-1

7 January 2021

Studies on the mechanism of a fatal clarithromycin-pimozide interaction in a patient with Tourette syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900397-1

7 January 2021

Interaction between warfarin and erythromycin

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900397-1

7 January 2021

Warfarin interaction with erythromycin

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900397-1

7 January 2021

Potential interaction between clarithromycin and warfarin.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900397-1

7 January 2021

Potential interaction between azithromycin and warfarin

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900397-1

7 January 2021

Increased hypoprothrombinemic effect of warfarin possibly induced by azithromycin

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900397-1

7 January 2021

Possible increased anticoagulation effect of warfarin induced by azithromycin

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900397-1

7 January 2021

10.1016/S0924-8579(01)00397-1

Identifiers

DOI

1 reference

1 August 2017

1 reference